MedPath

Mobile Technology for Blood Pressure Management

Not Applicable
Completed
Conditions
Hypertension
Interventions
Combination Product: Mobile technology intervention
Registration Number
NCT04841317
Lead Sponsor
Stanford University
Brief Summary

The primary objective of this study is to assess the feasibility and effectiveness of a mobile-technology based system that integrates patient-facing and clinician-facing components to assist the management of hypertension.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
31
Inclusion Criteria
  • 18 years or older with an established diagnosis of essential hypertension
Read More
Exclusion Criteria
  • Patients on more than 2 antihypertensives at time of enrollment
  • Clinical diagnosis of secondary hypertension, that is, hypertension due to a secondary cause, including but not limited to the following:
  • Renal artery stenosis
  • Primary hyperaldosteronism
  • Cushing syndrome
  • Coarctation of the aorta
  • Drug-induced hypertension
  • Pheochromocytoma
  • Obstructive sleep apnea
  • Hospitalization for malignant hypertension or severe hypertension (including stroke, cardiac events, acute kidney injury) in the preceding 6 months
  • Hospitalization for unstable angina or myocardial infarction in the preceding 6 months
  • Prior diagnosis of heart failure or cardiomyopathy
  • Stroke or transient ischemic attack within prior 6 months
  • Prior organ transplantation
  • Failure to obtain informed consent
  • Pregnant or currently trying to become pregnant
  • Patients who are enrolled in other research studies
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Single-arm: Blood pressure interventionMobile technology interventionParticipants will use a mobile technology system comprising of a remote home blood pressure monitoring cuff and a mobile application integrated with a clinician-facing component to view and manage remote blood pressures. Participants will use this for 12 weeks, with assessment of blood pressure outcomes and anonymous surveys regarding the technology at 12 weeks.
Primary Outcome Measures
NameTimeMethod
Participant Survey12 weeks

A survey regarding usability and feedback about the intervention completed by participants. Questions 1 through 5 were rated on a scale of 1 (strongly disagree) to 7 (strongly agree); question 6 was rated on a scale of 1 (extremely confident) to 5 (extremely doubtful).

Physician Survey12 weeks

A survey regarding usability and feedback about the intervention completed by physicians. Physicians provided survey responses, but were not enrolled in the study. Questions 1, 2, and 3 were rated on a scale of 1 (strongly agree) to 7 (strongly disagree); question 4 was rated on a scale of 1 (extremely confident) to 5 (extremely doubtful); question 5 was rated on a scale of 1 (extremely pleased) to 7 (extremely displeased).

Change in Blood PressureAssessed at baseline and week 12

Change in systolic and diastolic blood pressure (SBP and DBP).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Stanford University

🇺🇸

Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath